Assessing the treatment effect of daratumumab by serial measurements of cardiac biomarkers and imaging parameters in light-chain cardiac amyloidosis.

ABSTRACT: Daratumumab, an anti-human CD38 monoclonal antibody, has become the standard of care in patients with systemic light-chain (AL) amyloidosis and multiple myeloma (MM). Herein, we report two cases of AL cardiac amyloidosis with MM who were treated with daratumumab, lenalidomide, and dexamethasone (DRd). Serial evaluation of cardiac biomarkers, echocardiography, and cardiac magnetic resonance imaging (CMR) were performed during 12 months of DRd treatment. A complete hematologic response was achieved three months after treatment initiation and sustained during the observation period. Twelve months after DRd treatment, we found improvements in levels (values for case 1 and case 2, respectively) of B-type natriuretic peptide (593.2 → 312.2 pg/mL and 202.4 → 104.3 pg/mL), N-terminal pro-brain nat

SUBMITTER: Tokai T 

PROVIDER: S-EPMC9508636 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature